Minocycline

General

Adult Dosing

  • IV or PO: 200 mg initial dose, then 100 mg q12h.

Pediatric Dosing

  • Avoided in children < 8 d/t calcium deposition in teeth
  • Children >8 years: PO, IV: 4 mg/kg/dose for 1 dose; Then 2 mg/kg/dose every 12 hours

Special Populations

  • Pregnancy Rating: D
  • Lactation:
  • Renal Dosing
    • Adult
    • Pediatric
  • Hepatic Dosing
    • Adult
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Common


Pharmacology

  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram PositiveStrep. Group A, B, C, GS
Strep. PneumoniaeS
Viridans strepX1
Strep. anginosus gpX1
Enterococcus faecalisR
Enterococcus faeciumR
MSSAS
MRSAI
CA-MRSAS
Staph. EpidermidisR
C. jeikeiumR
L. monocytogenesS
Gram NegativesN. gonorrhoeaeI
N. meningitidisS
Moraxella catarrhalisS
H. influenzaeS
E. coliS
Klebsiella spI
E. coli/Klebsiella ESBL+I
E coli/Klebsiella KPC+R
Enterobacter sp, AmpC negR
Enterobacter sp, AmpC posR
Serratia spX1
Serratia marcescensR
Salmonella spI
Shigella spI
Proteus mirabilisX1
Proteus vulgarisR
Providencia sp.X1
Morganella sp.X1
Citrobacter freundiiX1
Citrobacter diversusX1
Citrobacter sp.X1
Aeromonas spX1
Acinetobacter sp.S
Pseudomonas aeruginosaR
Burkholderia cepaciaI
Stenotrophomonas maltophiliaR
Yersinia enterocoliticaR
Francisella tularensisX1
Brucella sp.S
Legionella sp.X2
Pasteurella multocidaX1
Haemophilus ducreyiR
Vibrio vulnificusS+'
MiscChlamydophila spS
Mycoplasm pneumoniaeS
Rickettsia spS
Mycobacterium aviumR
AnaerobesActinomycesS
Bacteroides fragilisI
Prevotella melaninogenicaS
Clostridium difficileX1
Clostridium (not difficile)S
Fusobacterium necrophorumX1
Peptostreptococcus sp.S

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

References

  1. Sanford Guide to Antimicrobial Therapy 2014
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.